Visão geral da empresa
Firefly Neuroscience, Inc. operates within the technology sector, specifically functioning in the software application industry, where it delivers neuroscientific solutions designed to enhance brain health outcomes for patients suffering from mental illnesses and neurological disorders. The company's core offering includes Brain Network Analytics, a specialized software platform that focuses on diagnostic capabilities within the medical technology and artificial intelligence landscape. As of the latest reporting period, the entity holds a market capitalization of $26.87M, while its annual revenue generated over the trailing twelve months amounts to $1.14M. The specific employee count is not disclosed in the available public data, which is common for early-stage software firms where intellectual capital outweighs headcount in valuation models. These financial figures indicate that the company is a small-cap entity with a market valuation significantly higher than its current revenue base, suggesting the market places a premium on its future growth potential and proprietary technology rather than current profitability. The substantial gap between the $26.87M market cap and the $1.14M revenue highlights that the stock price is driven by expectations of future expansion and technological adoption rather than established cash flow generation.
Saúde financeira
The company reported revenue of $1.14M over the trailing twelve months, yet it posted a net income loss of $-24,531,000, revealing a cost structure where operating expenses vastly exceed revenue generation. This discrepancy results in an EBITDA of $-8,464,000, indicating that the business is currently burning cash to fund its research and development activities rather than producing immediate profits. Free cash flow stands at $-6,578,250, which signifies that the company is in a capital-intensive phase of expansion where it must rely on external financing or existing reserves to fund operations and growth initiatives. Margin analysis shows a gross margin of 56.5%, suggesting efficient production of its software products, but this is contrasted by an operating margin of -583.0% and a profit margin of 0.0%, illustrating that high overhead costs are consuming all operating income. The balance sheet reflects a cash position of $2.75M against zero debt, creating a scenario where the company has no financial leverage and is entirely funded by equity. This lack of debt is confirmed by a debt-to-equity ratio of N/A, indicating a conservative capital structure that avoids interest obligations but limits financial flexibility during downturns. Liquidity is maintained with a current ratio of 1.43, which suggests the company possesses sufficient current assets to cover its short-term liabilities without immediate refinancing needs. Return on Equity is -547.6% and return on assets is -70.9%, metrics that reveal management is currently generating negative returns on the capital invested by shareholders and utilized in asset operations. These negative return figures are typical for high-growth technology companies that prioritize reinvestment in R&D over shareholder returns during their developmental stages.
Avaliação de valorização
Valuation metrics present a complex picture given the absence of normalized earnings, as the trailing P/E and forward P/E ratios are both listed as N/A due to the company's net losses. The price-to-book ratio is 3.13, which indicates that the market is pricing the company at a significant premium relative to its tangible book value, reflecting high expectations for future intangible asset appreciation. Alternative valuation measures such as the price-to-sales ratio of 23.53 and an EV/EBITDA of -2.66 provide context for investors analyzing the stock without relying on profit-based multiples. The stock has traded within a 52-week range between a low of $0.62 and a high of $4.51, with the current market price sitting somewhere within this band depending on the day of observation. The beta value is listed as N/A, meaning that historical volatility data relative to the broader market is unavailable or insufficient to calculate a standard deviation metric for this specific stock. Without a calculated beta, investors cannot quantify the stock's sensitivity to market movements using standard statistical models, which adds a layer of uncertainty to risk assessment strategies. The high price-to-sales figure combined with the negative EV/EBITDA suggests that valuation is purely speculative, driven by the potential success of the Brain Network Analytics platform rather than current financial performance.
Growth & Income
Revenue growth over the past year is an impressive 677.4%, demonstrating rapid expansion in sales volume or market penetration, while earnings growth is N/A due to the company's ongoing net losses. Because the earnings growth metric is unavailable, it is impossible to compare the rate of earnings growth against revenue growth, but the massive revenue increase implies that the top-line business model is scaling effectively. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, indicating that all available earnings and cash reserves are being retained and reinvested into the business for growth purposes rather than distributed to shareholders. This reinvestment strategy is typical for technology firms in the software application industry that require continuous funding for R&D to maintain competitive advantages in the artificial intelligence and neuroscientific solutions space. The overall growth and income profile is characterized by high revenue acceleration coupled with a complete absence of current profitability or dividend income, positioning the stock as a high-risk, high-potential growth vehicle for investors with a long-term horizon.